Autolus Therapeutics is known for developing, manufacturing, and delivering next-generation programmed T cell therapies. AUCATZYL® is their proprietary CD19-directed CAR T cell therapy ...

Autolus has picked up its first ... (obecabtagene autoleucel or obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor ALL based on the results of the phase 2 FELIX ...

Germany’s BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies. The main thrust ...

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a ... while limiting the overactivation of any one CAR-T cell. This apparently improves the molecule ...

Autolus expects to complete authorization ... AUCATZYL is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy designed to overcome the limitations in clinical ...

Autolus’ Phase 1b/2 clinical trial of obe ... AUCATZYL is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy designed to overcome the limitations in clinical ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy (REMS) programme. Developer Autolus set a list price of $525,000 for its ...

Autolus expects to complete authorization of the first 30 ... AUCATZYL is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy designed to overcome the limitations in ...